ClariVest Asset Management’s Nektar Therapeutics NKTR Stock Holding History

ClariVest Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Hold	0	–	–	–	710
2019 Q1	–	Hold	0	–	–	–	756
2018 Q4	–	Hold	0	–	–	–	740
2018 Q3	–	Sell	-1,147	Closed	-$839K	–	766
2018 Q2	$839K	Sell	1,147 -3,410	-75%	-$3.93M	0.01%	464
2018 Q1	$7.26M	Buy	4,557 +1,340	+42%	+$1.73M	0.13%	140
2017 Q4	$2.88M	Buy	+3,217	New	+$1.9M	0.05%	280

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

ClariVest Asset Management's NKTR Position: Q2 2019 in Review

ClariVest Asset Management held its Nektar Therapeutics (NKTR) position steady in Q2 2019 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #710.

ClariVest Asset Management first reported a position in NKTR in Q4 2017 and has held it in 3 quarters since. The position peaked at $7.26M in Q1 2018. 336 funds tracked by Wall St. Rank hold NKTR as of Q2 2019.

ClariVest Asset Management held 0 shares of Nektar Therapeutics worth $0 as of Q2 2019.
ClariVest Asset Management left its Nektar Therapeutics share count unchanged in Q2 2019.
Nektar Therapeutics made up ﹤0.01% of ClariVest Asset Management's portfolio in Q2 2019, its #710 holding.
ClariVest Asset Management first reported a position in Nektar Therapeutics in Q4 2017 and has held it in 3 quarters since.
ClariVest Asset Management's Nektar Therapeutics position peaked at $7.26M in Q1 2018.
336 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2019.

Based on ClariVest Asset Management's 13F filing for Q2 2019, filed 9 Aug 2019.